(To join our email list, click here) by TrialSite Staff U.S-based Novavax (Nasdaq: NVAX) reports today that its COVID-19 vaccine candidate called NVX-CoV2373 or “Coronavax” demonstrated 100% protection against moderate and severe disease and 90.4% overall efficacy, keeping this investigational product competitive with both mRNA-based vaccine products under emergency use … Continue reading Breaking News Novavax’ Traditional Vaccine Brings Imminent Competition to the Genetic-based Vaccines Currently Under EUA [June 14, 2021]